AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Diagnostic and Therapeutic Pearls in Dermatology

Description

In a session led by Mark Lovewell, Chair Emeritus of Dermatology at Mount Sinai, the talk focused on innovative diagnostic and therapeutic strategies in dermatology, particularly regarding acne treatment. Recent changes to the I Pledge program for treating acne with isotretinone have alleviated some restrictions, simplifying the process for physicians and patients. Lovewell discussed the efficacy of isotretinone for various skin conditions, emphasizing its rapid response in treating difficult cases like perioral dermatitis and ashydermatosis. He also addressed concerns about isotretinone's association with inflammatory bowel disease and depression, presenting studies suggesting no significant links between isotretinone and these conditions. Moreover, he shared successful case studies involving the use of retinoids in managing skin cancers and squamous cell carcinomas, highlighting the potential of newer therapies, including the HPV vaccine for treating recalcitrant warts and innovative medications for conditions like pyoderma gangrenosum. Lovewell concluded by underscoring the importance of expanding the use of emerging therapies in dermatology to improve patient outcomes.

View more

Conclusions

  • Recent modifications to the iPledge program have simplified the process for prescribing isotretinoin, making it more accessible to patients.
  • Isotretinoin is effective for treating various conditions beyond acne, such as lichen planus and perioral dermatitis.
  • There is no conclusive evidence linking isotretinoin to inflammatory bowel disease, suggesting that the risk is more associated with the condition of acne itself rather than the medication.
  • Patients taking isotretinoin may not have an elevated risk of depression or suicide compared to those not using the medication.
  • Isotretinoin has demonstrated benefits in preventing recurrence of squamous cell carcinoma in certain patient populations.
  • New treatments, such as the 9-valent HPV vaccine and the use of JAK inhibitors, show promise for treating dermatological conditions and enhancing patient outcomes.
  • Camisa C, Allen CM. Treatment of oral erosive lichen planus with systemic isotretinoin. Oral Surg Oral Med Oral Pathol. 1986; 62:393-6.
  • Low-dose oral isotretinoin therapy in lichen planus pigmentosus: an open-label non-randomized prospective pilot study. Int J Dermatol. 2016 Sep;55:1048-54.
  • Atacan D, Ergin C, Çelik G, Gönül M, Adabağ A. Oral isotretinoin: A new treatment alternative for generalized lichen amyloidosis. Australas J Dermatol. 2016;57:246-7.
  • Spano F, Donovan JC. Efficacy of oral retinoids in treatment-resistant lichen planopilaris. J Am Acad Dermatol. 2014;71:1016-8.
  • Rodriguez-Garijo N, et al. Recalcitrant granulomatous periorificial dermatitis with good response to low-dose oral isotretinoin. Pediatr Dermatol. 2019;36:980-981.
  • Smith KW. Perioral dermatitis with histopathologic features of granulomatous rosacea: successful treatment with isotretinoin. Cutis. 1990;46:413-5.
  • Diaz A, Gillihan R, Motaparthi K, Rees A. Combination Therapy with Prednisone and Isotretinoin in Early Erythema Dyschromicum Perstans: A Retrospective Series. JAAD Case Reports. 2020 Feb 19;6(3):207-213.
  • Leung N, Oliveira M, Selim MA, McKinley-Grant L, Lesesky E. Erythema Dyschromicum Perstans: A Case Report and Systematic Review of Histologic Presentation and Treatment. International Journal of Women's Dermatology. 2018 Sep 27;4(4):216-222.
  • Wang F, Zhao YK, Wang Z, Liu JH, Luo DQ. Erythema Dyschromicum Perstans Response to Isotretinoin. JAMA Dermatology. 2016 Jul 1;152(7):841-2.
  • deBruno NP, Beacham BE, Burnett JW. Adverse effects of isotretinoin therapy. Cutis. 1984;33:484-9.
  • Crockett SD et al. Isotretinoin use and the risk of inflammatory bowel disease: a case-control study. Am J Gastroenterol 2010.
  • Stobaugh DJ et al. Alleged isotretinoin-associated inflammatory bowel disease: Disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System. JAAD 2013 Sep;69(3):393-8.
  • Alhusayen RO, Juurlink DN, Mamdani MM, Morrow RL, Shear NH, Dormuth CR. Isotretinoin Use and the Risk of Inflammatory Bowel Disease: A Population-Based Cohort Study. J Invest Dermatol. 2013;133:907-912.
  • Margolis DJ, Fanelli M, Hoffstad O, Lewis JD. Potential Association Between the Oral Tetracycline Class of Antimicrobials Used to Treat Acne and Inflammatory Bowel Disease. Am J Gastroenterol. 2010 Aug 10.
  • Etminan M et al. Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data. JAMA Dermatol. 2013;149(2):216-20.
  • Racine A, Cuerq A, Bijon A, et al. Isotretinoin and risk of inflammatory bowel disease: a French nationwide study. Am J Gastroenterol. 2014;109:563-569.
  • Rashtak S, Khaleghi S, Pittelkow MR, Larson JJ, Lahr BD, Murray JA. Isotretinoin Exposure and Risk of Inflammatory Bowel Disease. JAMA Dermatol. 2014;150:1322-1326.
  • Kridin K, Ludwig RJ. Isotretinoin and the risk of inflammatory bowel disease and irritable bowel syndrome: A large-scale global study. J Am Acad Dermatol. 2023;88:824-830.
  • Kridin K, Ludwig RJ. Isotretinoin and the risk of psychiatric disturbances: A global study shedding new light on a debatable story. J Am Acad Dermatol. 2023;88:388-394.
  • Bachmann C et al. Isotretinoin, depression and suicide ideation in an adolescent boy. Pharmacopsychiatry. 2007;40(3):128.
  • Kim KH et al. Phase 1 clinical trial of intralesional injection of Candida antigen for the treatment of warts. Arch Dermatol. 2010;146:1431-3.